

Attorney Docket No.: RTS-0212
Inventors: Ward and Watt
Serial No.: 09/954,679
Filing Date: September 12, 2001
Page 2

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (currently amended): A compound 6 to 50 nucleobases in length targeted to a nucleic acid molecule encoding ribonuclease L (SEQ ID NO: 3), wherein said compound specifically hybridizes with said nucleic acid molecule encoding ribonuclease L and inhibits the expression of ribonuclease L.

Claim 2 (original): The compound of claim 1 which is an antisense oligonucleotide.

Claim 3 (canceled)

Claim 4 (original): The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.

Attorney Docket No.: RTS-0212
Inventors: Ward and Watt
Serial No.: 09/954,679
Filing Date: September 12, 2001
Page 2

Claim 5 (original): The compound of claim 4 wherein the modified internucleoside linkage is a phosphorothioate linkage.

Claim 6 (original): The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified sugar moiety.

Claim 7 (original): The compound of claim 6 wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.

Claim 8 (original): The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified nucleobase.

Claim 9 (original): The compound of claim 8 wherein the modified nucleobase is a 5-methylcytosine.

Claim 10 (original): The compound of claim 2 wherein the antisense oligonucleotide is a chimeric oligonucleotide.

Claim 11 (currently amended): A compound 8 to 50 nucleobases in length which specifically hybridizes with at least an 8-nucleobase

Attorney Docket No.: RTS-0212
Inventors: Ward and Watt
Serial No.: 09/954,679
Filing Date: September 12, 2001
Page 4

portion of an active site on a nucleic acid molecule encoding ribonuclease L (SEQ ID NO: 3).

Claim 12 (original): A composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier or diluent.

Claim 13 (original): The composition of claim 12 further comprising a colloidal dispersion system.

Claim 14 (original): The composition of claim 12 wherein the compound is an antisense oligonucleotide.

Claim 15 (original): A method of inhibiting the expression of ribonuclease L in cells or tissues comprising contacting said cells or tissues with the compound of claim 1 so that expression of ribonuclease L is inhibited.

Claim 16 (original): A method of treating an animal having a disease or condition associated with ribonuclease L comprising administering to said animal a therapeutically or prophylactically

Attorney Docket No.: RTS-0212
Inventors: Ward and Watt
Serial No.: 09/954,679
Filing Date: September 12, 2001
Page 5

effective amount of the compound of claim 1 so that expression of ribonuclease L is inhibited.

Claim 17 (original): The method of claim 16 wherein the disease or condition results from an infection.

Claim 18 (original): The method of claim 16 wherein the disease or disorder arises from aberrant apoptosis.

Claim 19 (original): The method of claim 16 wherein the disease or condition is cancer.

Claim 20 (original): A method of modulating the process of RNA-mediated interference (RNAi) in a cell or animal comprising administering to said cell or animal a therapeutically or prophylactically effective amount of the compound of claim 1 so that expression of ribonuclease L is inhibited.